Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sanofi 2 ADR Representing Ord Shs SNY

Healthcare
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Recent & Breaking News (NDAQ:SNY)

Sanofi explores combination treatments for multiple myeloma in new late-stage trials

Business Wire December 7, 2017

Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec

GlobeNewswire December 4, 2017

Sanofi ends development of Clostridium difficile vaccine

GlobeNewswire December 1, 2017

Switching to Toujeo® in a real-world setting produced a similar number of severe low blood sugar events as insulin degludec

PR Newswire November 30, 2017

Sanofi updates information on dengue vaccine

GlobeNewswire November 29, 2017

Free Research Reports on These Healthcare Stocks -- Sanofi, DURECT, Sucampo Pharma, and Perrigo

PR Newswire November 28, 2017

Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy

GlobeNewswire November 2, 2017

Sanofi to Host Earnings Call

Accesswire November 2, 2017

Sanofi : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed

GlobeNewswire November 2, 2017

Sanofi : Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma

GlobeNewswire October 31, 2017

Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron Therapeutics, and Aerie Pharma

PR Newswire October 20, 2017

Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis

PR Newswire October 16, 2017

Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis

PR Newswire October 11, 2017

New Label For Afrezza Could Turn Things Around At MannKind

Benzinga.com  October 10, 2017

Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)

PR Newswire October 5, 2017